01 10Noxafil
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 329
2019 Revenue in Millions : 662
Growth (%) : -50
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 259
2020 Revenue in Millions : 329
Growth (%) : -21
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 238
2021 Revenue in Millions : 259
Growth (%) : -8
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2023 Revenue in Millions : 213
2022 Revenue in Millions : 238
Growth (%) : -11
Main Therapeutic Indication : Anti-fungal
Currency : USD
2015 Revenue in Millions : 402
2014 Revenue in Millions : 487
Growth (%) : 21%
Main Therapeutic Indication : Anti-fungal
Currency : USD
2014 Revenue in Millions : 30.10%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Anti-Fungal
Currency : USD
2016 Revenue in Millions : 595
2015 Revenue in Millions : 487
Growth (%) : 22
Main Therapeutic Indication : Anti-fungal
Currency : USD
2017 Revenue in Millions : 636
2016 Revenue in Millions : 595
Growth (%) : 7
Main Therapeutic Indication : Anti-Fungal
Currency : USD
2018 Revenue in Millions : 742
2017 Revenue in Millions : 636
Growth (%) : 17%
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2019 Revenue in Millions : 662
2018 Revenue in Millions : 742
Growth (%) : -11
LOOKING FOR A SUPPLIER?